Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines

Biomaterials

Volumn 19, Issue 11-12, 1998, Pages 1073-1081

  Coombes, A G A ^a,c   Major, D ^b   Wood, J M ^b   Hockley, D J ^b   Minor, P D ^b   Davis, S S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Adjuvant; Adsorption; Influenza; Polylactide; Vaccine

Indexed keywords

ADSORPTION; ANTIGEN-ANTIBODY REACTIONS; BIOCOMPATIBILITY; COPOLYMERS; POLYESTERS; SUBSTRATES; VACCINES; VIRUSES;

POLYLACTIDE;

BIOMATERIALS;

ADJUVANT; COPOLYMER; HEMAGGLUTININ; INFLUENZA VACCINE; POLYLACTIDE;

ADSORPTION; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; INFLUENZA VIRUS; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; LACTIC ACID; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; MICROSCOPY, ELECTRON, SCANNING; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PARTICLE SIZE; PHAGOCYTES; POLYESTERS; POLYGLYCOLIC ACID; POLYMERS;

ANIMALIA; INFLUENZA VIRUS;

EID: 17944396142     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(98)00035-0     Document Type: Article

References (29)

1. [1] Khan MZI, Optebeeck JP, Tucker IG. Immunopotentiation and delivery systems for antigens for single-step immunisation, recent trends and progress. Pharm Res 1994;11:2-11.
2. [2] Coombes AGA, Meikle MC. Resorbable synthetic polymers as replacements for bone graft. Clinical Mater 1994;17:35-67.
3. [3] Lewis DH. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chassin H, Langer R, editors. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, 1990:1-41.
4. [4] Morris W, Steinhoff MC, Russel PK. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994; 12:5-11.
5. [5] Park TG, Lu WL, Crotts G. Importance of in vitro experimental conditions on protein release kinetics stability and polymer degradation in protein encapsulated poly(DL lactic acid coglycolic acid) microspheres. J Controlled Rel 1995;33:211-22.
6. [6] O'Hagan DT, Jeffery H, Davis SS. Long term antibody responses in mice following subcutaneous immunisation with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993;11:965-9.
7. [7] Kreuter J, Liehl E, Berg U, Soliva M, Speiser PP. Influence of hydrophobicity on the adjuvant effect of particulate polymeric adjuvants. Vaccine 1988;6:253-6.
8. [8] Alpar HO, Almeida AJ. Identification of some of the physicochemical characteristics of microspheres which influence the induction of the immune response following mucosal delivery. Eur J Pharm Biopharm 1994;40:198-202.
9. [9] Couch RB, Keitel WA, Cate TR, Quarles JA, Taber LA, Glezen WP. Prevention of influenza virus infections by current influenza virus vaccines In: Brown LE, Hampson AW, Webster RG, editors. Options for the control of Influenza III. Amsterdam: Elsevier, 1996:97-106.
10. [10] Fessi H, Devissaguet JP, Puissieux F, Thies C. Demande de Brevet D'Invention. No 2608988. Republique Franc;aise, 1986.
11. [11] Washington C. Particle size analysis in pharmaceutics and other industries: theory and practice. Ch. 7. Chichester, England: Ellis Horwood Ltd., 1992.
12. [12] Fischer FW, Sterzel HJ, Wegner G. Investigation of the structure of solution grown crystals of lactide copolymers by means of chemical reaction. Kolloid-Z u Z. Polymere 1973;251:980-90.
13. [13] Wood JM, Schild GC, Newman RW, Seagroatt VJ. An improved single radial immunodiffusion technique for the assay of influenza haemagglutinin antigen. Application for potency determinations of inactivated whole and subunit vaccines. J Biol Std 1977;5:237-47.
14. [14] Alemann E, Gurny R, Doelker E. Drug-loaded nanoparticles -preparation methods and drug targeting issues. Eur J Pharm Biopharm 1993;39:173-91.
15. [15] Dunn S, Coombes AGA, Garnett MC, Davis SS, Davies MC, Illum L. In vitro cell interaction and in vivo biodistribution of poly(lactide co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. J Control Release 1997; 44:65-76.
16. [16] Stolnik S, Davies MC, Illum L, Davis SS, Bousta M, Vert M. The preparation of sub-200 nm biodegradable colloidal particles from poly(B-malic acid-co-benzyl malate) copolymers and their surface modification with poloxamer and poloxamine surfactants. J Control Release 1994;30:57-67.
17. [17] Bodmeier R, Chen H, Tyle P, Jarosz P. Spontaneous formation of drug-containing acrylic nanoparticles. J Microencapsulation 1991; 8:161-70.
18. [18] Kalb B, Pennings AJ. General crystallisation behaviour of poly(L-lactic acid). Polymer 1980;21:607-12.
19. [19] Coombes AGA, Heckman JD. Gel casting of resorbable polymers. 1 Processing and applications. Biomaterials 1992;13: 217-24.
20. [20] Christel P, Chabot F, Leray FL, Morin C, Vert M. Biodegradable composites for internal fixation. In: Winter GD, Giobbones DF, Plenk H, editors. Biomaterials. New York: J Wiley 1982; 271-80.
21. [21] Schild GC, Robertson JS, Wood JM. Influenza viruses and vaccines. In: Myint S, Tayor-Robinson D, editors. Viral and other infections of the human respiratory tract. London: Chapman & Hall, 1996:251-74.
22. [22] Gray D, Skarvall H. B-cell memory is short lived in the absence of antigen. Nature 1988;336:70.
23. [23] Espartza I, Kissel T. Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. Vaccine 1992;10:714-20.
24. [24] Suming Li, Garreau H, Vert M. Structure property relationships in the case of the degradation of massive poly(α-hydroxy acids) in aqueous media. Part 3. Influence of the morphology of poly(L-lactic acid). J Mater Sci Mater Med 1990;1:188-206.
25. [25] Keller A. Solution grown polymer crystals. Kolloid-Z u Z. Polymere 1969;231:386-421.
26. [26] Pizzoferrato A, Ciapeti G, Stea S, Toni A. Cellular events in the mechanisms of prosthesis loosening. Clin Mater 1993;7: 51-81.
27. [27] Pappas MA, Schmidt CC, Shanbhag AS, Whiteside TA, Rubash HE, Herndon JH. Biological response to particulate debris from non-metallic orthopaedic implants. In: Wise DL, Trantolo DJ, Altobelli DE, Yaszemski MJ, Gresser DD, editors. Handbook of biomaterials applications. Totowa NJ: Humana Press, 1996: 115-36.
28. [28] Matlaga B, Yasenchak L, Salthouse T. Tissue response to implanted polymers. The significance of sample shape. J Biomed Mater Res 1976;10:391-97.
29. [29] Visscher GE, Pearson JE, Fong JW, Argentieri GJ, Robison RL, Maulding HV. Effect of particle size on the in vitro and in vivo degradation rates of poly(DL lactide co-glycolide) microcapsules J Biomed Mater Res 1988;22:733-46.